Overview

Topical MAPK Inhibition in Rosacea

Status:
Recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea

Phase:

Phase 1

Details

Lead Sponsor:

Albany Research Institute, Inc.

Treatments:

Trametinib